Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

Novo Nordisk

Status and phase

Completed

Phase 1

Conditions

Diabetes

Diabetes Mellitus, Type 2

Treatments

Drug: placebo

Drug: liraglutide

Study type

Interventional

Funder types

Industry

Identifiers

NCT01507311

NN2211-1219

Details and patient eligibility

About

This trial is conducted in Europe. The aim of this trial is to assess the effect of NNC 90-1170 (liraglutide) on pulsatile insulin secretion and insulin secretion after a standard meal in subjects with type 2 diabetes.

Enrollment

11 patients

Sex

All

Ages

30 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosed with type 2 diabetes, either newly diagnosed with at least two months of diet treatment, or in current OHA (oral hypoglycaemic agent) treatment with stable dose for at least six months
BMI (Body Mass Index) between 24 and 35 kg/m^2 (both inclusive)
Fasting plasma glucose between 6 and 15 mmol/l (both inclusive)
Anti-GAD (glutamic acid decarboxylase) negative

Exclusion criteria

Known or suspected allergy to trial product or related products
Receipt of any investigational drug within three months prior to this trial
Recurrent severe hypoglycaemia as judged by the investigator
Cardiac disease or any clinically significant abnormal ECG (electrocardiogram)
Use of any drug (except oral hypoglycaemic agents (OHAs)) which in the investigator's opinion could interfere
with the blood glucose level (i.e., insulin, systemic corticosteroids, thiazides)
Liver or renal disease